Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Adaptvac Aps has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 2 distinct examiners and 2 distinct art units. This distribution shows that the company is engaging with multiple specialized sections of the patent office simultaneously.
LU, CHENG is the busiest examiner for the portfolio. This examiner is currently handling 1 pending office action. Because there are 2 distinct examiners for 2 pending actions, the workload is evenly divided across the identified art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LU, CHENG | 1 | 53.8% | +64.6% |
| JAUHARI, SACHI | 1 | 60.0% | +80.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18257554 | NUCLEIC ACID VACCINES | LU, CHENG | — |
| 17917214 | PEPTIDE TAGS AND BINDING PARTNERS | JAUHARI, SACHI | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18257554 | NUCLEIC ACID VACCINES | LU, CHENG | 1671 | §103§112DP | Non-Final OA | — | Pending | Jun 14, 2023 |
| 17917214 | PEPTIDE TAGS AND BINDING PARTNERS | JAUHARI, SACHI | 1654 | §112 | Non-Final OA | — | Pending | Oct 05, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAdaptvac Aps has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Cheng Lu has the most, with 1 of Adaptvac Aps's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
